Valuation: Avacta Group Plc

Market Cap 302M 408M 354M 331M 568M 38.92B 577M 3.9B 1.52B 19.49B 1.53B 1.5B 64.98B P/E 2026 *
-9.22x
P/E 2027 * -9.51x
Enterprise Value 297M 401M 347M 325M 558M 38.2B 566M 3.82B 1.49B 19.13B 1.5B 1.47B 63.78B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Avacta Group Plc

1 day+0.62%
1 week-5.84%
Current month-3.01%
1 month-5.84%
3 months-24.56%
6 months+10.26%
Current year+11.21%
1 week 63
Extreme 63
74.5
1 month 63
Extreme 63
74.5
Current year 48
Extreme 48
92
1 year 45
Extreme 45
92
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 2024-03-31
Director of Finance/CFO 51 2025-01-21
Chief Tech/Sci/R&D Officer - 2026-02-08
Director TitleAgeSince
Director/Board Member 60 2020-02-02
Director/Board Member 71 2021-08-16
Director/Board Member 56 2022-03-17
Date Insider Type Main position Quantity % Market Cap.
9/2/24 Sell

Chief Financial Officer

500,000 0.1393%
9/2/24 Free

Chief Executive Officer

3,600,000 1.0027%
9/2/24 Fiscal year

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%-5.84%+43.33%-39.44% 406M
-0.73%+7.82%+73.81%+102.34% 70.51B
+1.60%+1.66%+37.76%+67.36% 54.05B
-0.22%+33.59%+8.43%+489.75% 28.95B
+0.04%+10.68%+48.70%+7.64% 24.05B
-0.06%+0.61%-16.45%-13.26% 23.31B
-1.37%+7.87%+251.71%+464.53% 18.67B
+2.21%+7.66%+47.18%-20.09% 18.37B
0.00%+3.94%+26.20%+623.29% 16.1B
-1.85%-11.15%+32.75%+134.11% 12.72B
Average +0.03%+7.14%+55.34%+181.62% 26.71B
Weighted average by Cap. +0.09%+9.56%+55.02%+168.22%

Financials

2026 *2027 *
Net sales - -
Net income -33.4M -45.12M -39.09M -36.62M -62.8M -4.3B -63.77M -431M -168M -2.15B -169M -166M -7.18B -32.74M -44.21M -38.31M -35.89M -61.54M -4.22B -62.49M -422M -165M -2.11B -166M -162M -7.04B
Net Debt -5.58M -7.53M -6.53M -6.12M -10.49M -718M -10.65M -71.92M -28.11M -360M -28.28M -27.67M -1.2B 21.72M 29.33M 25.41M 23.81M 40.83M 2.8B 41.46M 280M 109M 1.4B 110M 108M 4.67B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
26-08-12 GBX 64.50 +0.62% 605,236
26-08-11 GBX 64.10 -1.38% 1,055,474
26-08-10 GBX 65.00 -2.99% 1,158,868
26-08-07 GBX 67.00 -0.74% 461,694
26-08-06 GBX 67.50 -1.46% 683,196
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6450GBP
Average target price
0.8167GBP
Spread / Average Target
+26.62%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVCT Stock